The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective
Type 2 Diabetes in the US Managed Care Setting: The Burden of Disease and Rationale for an Oral Glucagon-like Peptide-1 Receptor Agonist